

Real world evidence scoping roundtable

	Tea, coffee and registration
	Welcome and introduction <i>Overview and recap of key themes from the 2015 workshop</i> Professor Sir Alasdair Breckenridge CBE FRSE FMedSci, Former Chair, MHRA
	US workshops on real world evidence: findings so far Dr Greg Simon, Senior Investigator, Kaiser Permanente Washington Health Research Institute
Real world data to real world evidence: how are we using real world evidence?	
	Medicines and Healthcare products Regulatory Agency Dr Katherine Donegan, Pharmacoepidemiology Research and Intelligence Unit Manager, MHRA
	European Medicines Agency Dr Alison Cave, Principal Scientific Administrator, EMA
	US Food and Drug Administration Dr Jacqueline Corrigan-Curay, Director, Office of Medical Policy, FDA
	Tea and coffee
	National Institute for Health and Care Excellence Ms Sheela Upadhyaya, Associate Director Highly Specialised Technologies, NICE
	Discussion 1: Where are we now and where do we want to be? <ul style="list-style-type: none"> • What progress has been made to date on using real world evidence, particularly for efficacy and effectiveness assessment? In particular, this might look to explore the themes from the 2015 workshop including: acceptability of RWE; methodologies; hierarchies of evidence; data infrastructure; capacity and capability. • Overall, what are the short-term, and long-term, aspirations for using real world evidence?
	Lunch
What is the vision for real world evidence in the future, and how can we achieve this?	
	Hierarchies of evidence: the acceptability of real world evidence Professor Andrew Morris FRSE FMedSci, Director, Health Data Research UK
	Discussion 2: What needs to be done to fully maximise on the potential of real world evidence? <ul style="list-style-type: none"> • What are the remaining challenges to using real world evidence; and how do these compare across the UK, Europe and globally? • What are the next steps to addressing some of these challenges? • In light of these discussions, what are the five key priorities for the next five years to overcome current challenges and enable the aspirations for using real world evidence to be met?
	Summary from the chair and close